68 results

  • adakveo

    (crizanlizumab)
    Novartis Pharmaceuticals Corporation
    ADAKVEO® is indicated for reducing the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 and older with sickle cell disease.

  • afinitor

    (everolimus)
    Novartis Pharmaceuticals Corporation
    AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

  • arranon - nelarabine injection

    (Nelarabine)
    Novartis Pharmaceuticals Corporation

  • arzerra - ofatumumab injection, solution

    (Ofatumumab)
    Novartis Pharmaceuticals Corporation

  • azopt - brinzolamide suspension/ drops

    (Brinzolamide)
    Novartis Pharmaceuticals Corporation

  • beovu

    (brolucizumab)
    Novartis Pharmaceuticals Corporation
    BEOVU® is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).

  • betoptic s

    (betaxolol hydrochloride)
    Novartis Pharmaceuticals Corporation
    BETOPTIC S (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

  • cipro

    (Ciprofloxacin Hydrochloride And Hydrocortisone)
    Novartis Pharmaceuticals Corporation

  • ciprodex - ciprofloxacin and dexamethasone suspension/ drops

    (Ciprofloxacin And Dexamethasone)
    Novartis Pharmaceuticals Corporation

  • coartem - artemether and lumefantrine tablet

    (Artemether And Lumefantrine)
    Novartis Pharmaceuticals Corporation